Search clinical trials for: Dapagliflozin

Total 1052 results

AstraZeneca

Completed

A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin

Type 2 Diabetes Mellitus

United States, Poland, Mexico, Hungary, Spain, Romania, South Africa, Denmark, Czechia, Sweden
HighTide Biopharma Pty Ltd
Shenzhen HighTide Biopharmaceutical Ltd.

Recruiting

Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

T2DM (Type 2 Diabetes Mellitus)

China
Centre Hospitalier Universitaire Dijon

Completed

Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes (Cinétique DAPA)

Type-2 Diabetes | Oral Antidiabetics

France
University of Guadalajara

Completed

Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension

PreDiabetes | Prehypertension

Mexico
AstraZeneca

Completed

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

Type II Diabetes

United States
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

Type 2 Diabetes

Mexico, United States, Argentina, Brazil, Canada
AstraZeneca
Bristol-Myers Squibb

Completed

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Type 2 Diabetes

Korea, Republic of, United States, Mexico, Puerto Rico, Philippines, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence

United States
Medanta, The Medicity, India
Diabetes & Endocrinology Foundation

Recruiting

Efficay and Safety of Empagliflozin Versus Sitagliptin for the In-patient Management of Hyperglycemia

Type 2 Diabetes

India
Shanghai Zhongshan Hospital

Recruiting

Canagliflozin and Myocardial Micro-perfusion

Cardiovascular Diseases | Type 2 Diabetes | Cardiac Perfusion Defect

China
Wake Forest University Health Sciences

Recruiting

SNIFF - Combo INI+EMPA Trial

Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment

United States
Amsterdam UMC, location VUmc

Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease

Netherlands
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers

Healthy

Belgium
Jeffrey Zonder

Not yet recruiting

DapagliFLOzin in Renal AL Amyloidosis (FLORAL) (FLORAL)

Renal AL Amyloidosis

United States
Medanta, The Medicity, India

Recruiting

Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus (EmLinaRenal)

Diabetes Mellitus | Kidney Transplant; Complications

India
Northwell Health

Withdrawn

The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products

Diabetes | SGLT-2 Inhibitors | Advanced Glycation End Products
AstraZeneca

Completed

Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea

Type 2 Diabetes Mellitus | Inadequate Glycaemic Control

Germany, Slovakia, Czechia, Hungary, Poland
Zhujiang Hospital
Third Affiliated Hospital, Sun Yat-Sen University; Peking University Shenzhen... and other collaborators

Completed

Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic Therapy

Type 2 Diabetes Mellitus

China
Boehringer Ingelheim

Completed

Esgliteo Post Marketing Surveillance (PMS) in Korean Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Korea, Republic of
Boehringer Ingelheim

Completed

Empa/Lina FDC Food Effect Study (Japan)

Healthy

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Australia, Brazil, Canada, El Salvador, France, Korea, Republic of, New Zealand, Norway, Spain, Taiwan
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Boston University
American Heart Association

Recruiting

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes (SFRNDM2)

Diabetes Mellitus, Type 2 | Endothelial Dysfunction

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Type 2 Diabetes Mellitus (T2DM)

United States
Research Clinical Centre of the Russian Railways...

Unknown

Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2

Diabetes Mellitus | Hypoglycemic Episodes

Russian Federation
National Institute of Allergy and Infectious Diseases...

Recruiting

Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency

Crohn's Disease | Glycogen Metabolism | Inflammatory Bowel Disease (IBD)

United States
Boehringer Ingelheim

Completed

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus

Sweden
Huashan Hospital

Unknown

A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy

Cardiomyopathies | Acromegaly

China
AstraZeneca
Bristol-Myers Squibb

Completed

Effects of Single Oral Dose Dapagliflozin QT Study

Healthy

United States
The Cleveland Clinic

Enrolling by invitation

Preoperative Education

Postoperative Pain

United States
Assiut University

Completed

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Heart Failure

Egypt
Centro de Diabetes Curitiba Ltda
AstraZeneca

Completed

Effect of Anti-diabetic Drugs on Glycemic Variability (EFFORT)

Diabetes Mellitus, Type 2

Brazil
Steno Diabetes Center Copenhagen
Bayer; AstraZeneca; Rigshospitalet, Denmark; The Novo Nordic Foundation

Completed

The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes

Obesity | Prediabetic State

Denmark
Clinical Nutrition Research Centre, Singapore
National University Hospital, Singapore

Completed

Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study (PSP)

Cardiometabolic Risk

Singapore
Lexicon Pharmaceuticals

Completed

Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Healthy Subjects

United States
Washington University School of Medicine
Children's Discovery Institute

Recruiting

Targeting Pediatric Brain Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Pediatric Brain Tumor

United States
Seoul National University Hospital

Unknown

Effect of Dapagliflozine on Systemic and Renal Endothelial Function

Type 2 Diabetes | Endothelial Function

Korea, Republic of
University of Campania "Luigi Vanvitelli"

Completed

Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (BEYOND)

Type 2 Diabetes

Italy
Boehringer Ingelheim

Completed

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

Healthy

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers

Healthy
McGill University Health Centre/Research Institute...
Diabetes Canada

Recruiting

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic Outcomes

Type 1 Diabetes

Canada
Xinhua Hospital, Shanghai Jiao Tong University...

Recruiting

Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Glycogen Storage Disease Type IB

China
Hong Kong Children's Hospital

Recruiting

Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin

Glycogen Storage Disease Type IB

Hong Kong
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 Years

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin

Diabetes Mellitus, Type 2

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)

Myocardial Infarction

United States, Spain, Australia, Denmark, Netherlands, Canada, China, Germany, Korea, Republic of, Israel, Hungary, Japan, Argentina, France, Romania, Russian Federation, Serbia, Ukraine, Poland, India, Brazil, Bulgaria

3

Subscribe